Sting­ing from a proxy loss and hun­gry for cash, Glax­o­SmithK­line bails on eq­ui­ty stake in In­no­vi­va for a tidy $392M

Fol­low­ing a failed at­tempt to chal­lenge a slate of new board can­di­dates at a com­pa­ny in which it’s a sig­nif­i­cant mi­nor­i­ty share­hold­er, Glax­o­SmithK­line has sold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER